Special CallCompany ParticipantsGuido Oelkers - CEO & PresidentMatthew WinfieldConference Call ParticipantsHerbert S.

The gout market is poised for steady growth, driven by the rising prevalence of the disease, increasing awareness, and the launch of novel therapies such as AR-882, Epaminurad, XNW3009, XRx-026, ...

The FDA has accepted for review the BLA for nanoencapsulated sirolimus plus pegadricase in the treatment of uncontrolled gout.